COMMUNIQUÉS West-GlobeNewswire

Novartis combination adjuvant therapy Tafinlar® + Mekinist® receives FDA Breakthrough Therapy Designation for stage III BRAF V600 mutation-positive melanoma patients

23/10/2017 - 07:15

Breakthrough Therapy Designation based on Phase III study showing the three-year relapse-free survival (RFS) rate for patients treated with the combination was 58%, compared to 39% with placebo[1] First targeted [...]

Strong Cresemba® (isavuconazole) sales in the United States trigger first sales milestone payment to Basilea

23/10/2017 - 07:15

Basel, Switzerland, October 23, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the sales of the antifungal Cresemba ® (isavuconazole) in the United States exceeded the threshold triggering the first [...]

ABLYNX ANNOUNCES WARRANT EXERCISE

23/10/2017 - 07:00

REGULATED INFORMATION GHENT, Belgium, 23 October 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that [...]

First International Consensus Statement on the Clinical and Therapeutic Management of LHON published in the Journal of Neuro-Ophthalmology

23/10/2017 - 07:00

Liestal, Switzerland, October 23, 2017 - Santhera Pharmaceuticals (SIX:SANN) announces that the first International Consensus Statement on the Clinical and Therapeutic Management of Leber's Hereditary Optic Neuropathy ( [...]

TiGenix granted Orphan Drug Designation from the U.S. FDA for Cx601

23/10/2017 - 07:00

PRESS RELEASE TiGenix granted Orphan Drug Designation from the U.S. FDA for Cx601 Leuven (BELGIUM) - October 23, 2017, 7:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company [...]

La FDA américaine accorde à TiGenix l'appellation de médicament orphelin pour le Cx601

23/10/2017 - 07:00

COMMUNIQUÉ DE PRESSE La FDA américaine accorde à TiGenix l'appellation de médicament orphelin pour le Cx601 Louvain (BELGIQUE) - 23 octobre 2017, 07h. CEST - TiGenix NV (Euronext Brussels et NASDAQ : TIG), société [...]

DBV Technologies annonce les résultats de l'étude clinique de phase III chez les enfants de 4 à 11 ans allergiques à l'arachide

20/10/2017 - 23:15

Communiqué de Presse Montrouge, France, le 20 Octobre; 10:35 pm CET DBV Technologies annonce les résultats de l'étude clinique de phase III chez les enfants de 4 à 11 ans allergiques à l'arachide DBV Technologies ( [...]

DBV Technologies Announces Topline Results of Phase III Clinical Trial in Peanut-Allergic Patients Four to 11 Years of Age

20/10/2017 - 23:15

Press Release Montrouge, France, October 20, 2017 DBV Technologies Announces Topline Results of Phase III Clinical Trial in Peanut-Allergic Patients Four to 11 Years of Age DBV Technologies (Euronext: DBV - ISIN: [...]

Silmäasema Oyj: Silmäasema supports the proposal of using client vouchers to pay for treating cataract and other eye diseases

20/10/2017 - 08:15

Silmäasema Corporation Press release 20 October 2017 at 9.15 EET Silmäasema supports the proposal of using client vouchers to pay for treating cataract and other eye diseases The draft government proposal regarding [...]

ThromboGenics Business Update - Q3 2017

20/10/2017 - 07:30

Press release 20 October, 2017 Regulated Information Diabetic Eye Disease programs progressing €53.7 million cash received from Alcon/Novartis in conjunction with regaining the non-US rights to JETREA Company's end Q3 [...]

Nicox : accord de recherche avec Re-Vana Therapeutics pour la nouvelle generation des donneurs de NO dans une forme ophtalmique novatrice à libération prolongée

20/10/2017 - 07:30

Communiqué de presse Nicox : accord de collaboration de recherche avec Re-Vana Therapeutics pour des donneurs d'oxyde nitrique purs de nouvelle génération dans une forme ophtalmique novatrice d'administration à [...]

Nicox Enters Research Collaboration with Re-Vana Therapeutics on its Next Generation of Stand-alone NO-donors in a Novel Sustained Release Ophthalmic Formulation

20/10/2017 - 07:30

Press Release Nicox Enters Research Collaboration with Re-Vana Therapeutics on its Next Generation of Stand-alone NO-donors in a Novel Sustained Release Ophthalmic Formulation October 20, 2017 - release at 7:30 am CET [...]

Publication dans la revue Journal of Clinical Investigation Insight de données précliniques montrant l'effet protecteur du masitinib sur le système nerveux périphérique dans la SLA

19/10/2017 - 17:43

Paris, 19 octobre 2017 , 17h45 Publication dans la revue Journal of Clinical Investigation Insight de données précliniques montrant l'effet protecteur du masitinib sur le système nerveux périphérique dans la sclérose [...]

Preclinical data showing protective effect of masitinib on the peripheral nervous system in ALS published in the Journal of Clinical Investigation Insight

19/10/2017 - 17:43

Paris, 19 October 2017 , 5.45pm Preclinical data showing protective effect of masitinib on the peripheral nervous system in amyotrophic lateral sclerosis (ALS) published in the Journal of Clinical Investigation Insight [...]

XBiotech annonce le premier patient dans une étude évaluant MABp1 en association avec Onivyde(R) et 5 fluorouracile / acide folinique pour le traitement du cancer du pancréas

19/10/2017 - 16:51

AUSTIN, Texas, le 19 octobre 2017 (GLOBE NEWSWIRE) - XBiotech Inc. (NASDAQ : XBIT) a annoncé aujourd'hui l'inscription du premier patient pour une étude de phase I à un seul groupe évaluant la dose maximale tolérée d' [...]

De nouveaux outils de recherche préclinique apportent une réponse immunitaire humanisée pour faire progresser le développement immunothérapeutique, webinaire en direct proposé par Crown Bioscience

19/10/2017 - 16:47

SANTA CLARA, Californie, le 19 octobre 2017 (GLOBE NEWSWIRE) - Crown Bioscience, filiale en propriété exclusive de Crown Bioscience International (TWSE : symbole boursier 6554) et société internationale de services de [...]

Notice to convene Herantis Pharma Plc's Extraordinary General Meeting of Shareholders

19/10/2017 - 15:30

Notice to convene Herantis Pharma Plc's Extraordinary General Meeting of Shareholders Herantis Pharma Plc Company release 19 October 2017, 4:30 pm NOTICE TO CONVENE HERANTIS PHARMA PLC'S EXTRAORDINARY GENERAL MEETING OF [...]

Herantis Pharma Plc is planning a directed share issue to a limited number of investors and the company's directors regarding the financing of the Lymfactin Phase 2 clinical study

19/10/2017 - 15:00

Herantis Pharma Plc is planning a directed share issue to a limited number of investors and the company's directors regarding the financing of the Lymfactin Phase 2 clinical study Herantis Pharma Plc Company release 19 [...]

Novel Preclinical Research Tools Provide Humanized Immune Response to Advance Immunotherapeutic Development, Live Webinar Hosted by Crown Bioscience

19/10/2017 - 14:00

SANTA CLARA, Calif., Oct. 19, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company [...]